Subcutaneous Formulation Articles & Analysis: Older
4 news found
The Phase 1 study met all of its primary and secondary endpoints; in all subjects dosed with STAR-LLD, the plasma lenalidomide concentration (AUC) was 57% lower with STAR-LLD continuous subcutaneous (SC) delivery compared to once-daily Revlimid oral delivery. ...
“Progressing to the final dosing interval marks a major milestone in our development program; this study has established the compatibility and utility of the continuous infusion device with our subcutaneous formulation. Lenalidomide has been an effective immunomodulatory drug in hematologic malignancies for years, however adverse events, notably ...
No. 10,973,780, describing pharmaceutical formulations and treatment methods including the company's BB106 ketamine therapy. Bexson believes the new utilities identified in this patent will allow safety, comfort and pharmacokinetics that greatly improve ketamine administration for multiple routes of administration, including subcutaneous. ...
Bexson Biomedical, Inc. will be co-hosting "The Ketamine Conference – A Molecular Masterclass" on August 21-22. The two-day virtual conference will include 12 different panel sessions focused on the latest science, clinical innovations, and investment opportunities with ketamine. Experts from around the globe will be participating as panel speakers and ...